Non-Hodgkin's Lymphoma Medical Reference

Learn about Mimrylo (rusfertide), an FDA-approved treatment for polycythemia vera (PV) that helps control red blood cell levels and reduce phlebotomies.

Beqalzi is a prescription targeted oral cancer medication. Here’s what side effects to expect and how to manage them.

Beqalzi is a prescription, targeted oral cancer medication. Here’s what drug interactions to be aware of.

Beqalzi is a prescription, targeted oral cancer medication. Here’s how it treats relapsed or refractory mantle cell lymphoma (MCL).

Komzifti is a once-daily oral medicine. Here’s how it treats acute myeloid leukemia.

Calquence is a Bruton tyrosine kinase inhibitor. Here’s how it treats chronic lymphocytic leukemia.

Even after treatment, acute myeloid leukemia can return. Here’s why — and how to manage the uncertainty.

Acute myeloid leukemia is a fast-growing cancer. Caring for your overall health can reduce treatment side effects and improve your quality of life.

Acute myeloid leukemia is a fast-growing cancer that needs treatment right away. Here’s what to expect.

Learn the alternatives to induction therapy and what to expect.

An overview of the first AML treatment you'll get, plus tips to help you prepare.

If you have diffuse large B-cell lymphoma (DLBCL), a good option is a treatment that uses your immune system. Learn about bispecific T-cell engagers.

CAR T-cell therapy is the preferred treatment for most people with refractory or relapsed DLBCL. Find out how it works and what to expect.

A direct B-cell cytolytic may be part of your treatment for refractory or relapsed DLBCL. Learn how they work, what they cost, and possible side effects.

Learn how antibody-drug conjugates help treat relapsed and refractory DLBCL: effectiveness, side effects, costs, and more.

Epkinly is a man-made antibody. Here’s how it treats lymphoma.

Asparlas is a chemotherapy medicine. Here’s how it treats acute lymphoblastic leukemia (ALL).

Copiktra is a PI3K inhibitor. Here’s how it treats chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Zydelig is a PI3K inhibitor. Here's how it treats chronic lymphocytic leukemia (CLL).

Find out how to set yourself up for success with CLL and learn about follow-up care, how to deal with side effects, and where to find support.

Rylaze is a chemotherapy medicine. Here’s how it treats acute lymphoblastic leukemia and lymphoblastic lymphoma.

Besremi is a type of immunotherapy. Here’s how it treats polycythemia vera.

Rytelo is a telomerase inhibitor. Here’s how it treats anemia in people with myelodysplastic syndromes (MDS).

When diffuse large B-cell lymphoma (DLBCL) returns or is hard to treat, here’s what you need to know about the financial aspects of the disease.

Learn how to manage some of the most common side effects of relapsed/refractory DLBCL treatments, including fatigue, digestive symptoms, and infection.

If you have a DLBCL relapse or your DLBCL doesn't respond to therapy, a growing number of second-line (2L) treatment options may help.

Treatment options for relapsed/refractory DLBCL include chemotherapy, immunotherapy, CAR T-cell therapy, stem cell transplant and more.

DLBCL may not respond to the first treatment. If yours comes back, you still have treatment options and possibly a chance at a cure.

Monjuvi is a monoclonal antibody. Here’s how it treats follicular lymphoma.

Marginal zone lymphoma is a group of rare blood cancers that start in your lymphatic system. This system helps your body fight infections. Many treatments can help because MZL is so slow-growing.

Breyanzi is an immunomodulator. Here’s how it treats large B-cell lymphoma.

Cytokine release syndrome is caused by excessive cytokine release, and it affects immunotherapy patients and those with autoimmune diseases or severe infections.

Polivy is a targeted cancer therapy. Here’s how it treats lymphoma.

Steroids can treat CLL and its complications, but they pose risks. Learn more about these treatments.

These drugs may be an option for CLL when other treatments fail. Learn more about PI3K inhibitors.

A targeted drug called a Bruton tyrosine kinase (BTK) inhibitor may be the first treatment you’re offered for CLL. Here’s what you need to know.

CLL treatment may include drugs that kill cancer cells either directly or by recruiting your immune system. Learn about these targeted therapies.

Jaypirca is a targeted cancer therapy. Here’s how it treats chronic lymphocytic leukemia.

Vonjo is a kinase inhibitor. Here’s how it treats myelofibrosis.

Jakafi is a JAK inhibitor. Here’s how it treats polycythemia vera (PV).

Imbruvica is a kinase inhibitor. Here’s how it treats two types of leukemia.

Lunsumio is an immunotherapy medicine. Here’s how it treats follicular lymphoma.

Jaypirca is a kinase inhibitor. Here’s how it treats mantle cell lymphoma.

Columvi is a type of immunotherapy. Here’s how it treats lymphoma.

Brukinsa is a targeted therapy. Here’s how it treats chronic lymphocytic leukemia and small lymphocytic lymphoma.

Venclexta is a targeted therapy for cancer. Here’s how it treats chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Zynlonta is a targeted therapy. Here’s how it treats B-cell lymphoma.

Scemblix is a tyrosine kinase inhibitor. Here’s how it treats chronic myeloid leukemia (CML).

Ojjaara is an oral Janus kinase (JAK) inhibitor. Here’s how it treats myelofibrosis with anemia.